← All drugs Report issue

tcmdc-140940

Small moleculeexperimental

Clinical trial activity

0 trials · 0 clinical orgs · 0 marketing orgs

Phase 1

0

Phase 2

0

Phase 3

0

Phase 4

0

Mechanism of action

Platelet-derived growth factor receptor betaINHIBITOR
PDGFRB inhibitor
Multi-targeted kinase irreversible inhibitor
- Platelet-derived growth factor receptor beta (PDGFRB) ↗
Tyrosine-protein kinase SRCINHIBITOR
SRC inhibitor
Multi-targeted kinase irreversible inhibitor
- Proto-oncogene tyrosine-protein kinase Src (SRC) ↗
Epidermal growth factor receptor erbB1INHIBITOR
EGFR inhibitor
Multi-targeted kinase irreversible inhibitor
- Epidermal growth factor receptor (EGFR) ↗
Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Multi-targeted kinase irreversible inhibitor
- Fibroblast growth factor receptor 1 (FGFR1) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1

Mol. weight: 512.44 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL49120 ↗
ChEMBLCHEMBL3545196 ↗

Also known as

pd-0166285
pd-0166285
tcmdc-140940
tcmdc-140940